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The increased level of plasma total homocysteine (tHcy) in chronic kidney disease patients has been reported as a new and
independent risk factor for cardiovascular disease. However, after the description of reverse epidemiology in the renal population,
theassociationoftHcyandnutritionbecamelessclear.Weevaluatedtheassociationbetweenhomocysteine,nutritionalstatus,and
inﬂammation, and their impact on mortality in 95 predialysis patients. High sensitivity C-Reactive Protein (hs-CRP), interleukin
6 (IL-6), Tumor Necrosis Factor α (TNF-α)], and tHcy were evaluated, as was the nutritional status by the modiﬁed Subjective
Global Nutritional Assessment (mSGA). We divided our population in four groups according to their tHcy and mSGA values
being above or below the mean level and found the lowest survival in the group with tHcy and mSGA above the mean level, as well
as higher levels of IL-6 (P = .03) and TNF-α (P = .045). Higher levels of homocysteine can be associated with higher mortality in
predialysis patients, as long as they are associated with malnutrition and inﬂammation.
1.Introduction
Homocysteine (Hcy) is an intermediate of methionine
metabolism. Hyperhomocysteinemia is frequent among
patientswithchronicrenalinsuﬃciency,althoughtheunder-
lying cause is not clearly understood. It seems to involve
reduced clearance of plasma Hcy, witch may be attributable
to defective renal clearance and/or extrarenal clearance and
metabolism, the latter possibly due to retained uremic
inhibitory substances [1].
Increased levels of Hcy have been associated to increased
overall mortality and to high mortality from cardiovascular
disease(CVD)[2,3].Allex ceptonestudy[4]describedsome
relation between vascular disease and Hcy levels. There is
also evidence that Hcy can alter the coagulation system and
the resistance of the endothelium to thrombosis [5]. It also
interfereswiththeantithrombotic andcoagulationfunctions
of nitric oxide [6].
Recent studies have reported a reversed epidemiology
in chronic kidney disease (CKD) patients where low, rather
then high plasma Hcy is an indicator of poor outcome
[7–10]. However, this association remains unclear because
wasting and inﬂammation seem to share the responsibility
for this reverse association, as they both decrease serum
albumin levels, witch are a major determinant of Hcy levels
[8]. In addition they are risk factors for increased morbidity
and mortality [8–11]. The aim of the present study was
to evaluate the association between Hcy levels, nutritional
status and inﬂammation, and their impact on mortality in
predialysis kidney patients.
2. Patients andMethods
We prospectively followed 95 patients at our low-clearance
outpatient clinic at Nephrology Department of Hospital de
Faro from August 2003 to August 2006. Informed consent
was obtained from all patients. At baseline, a complete
clinical history and a physical examination were performed.
Patientswereconsideredtohavehypertensionifsittingblood
pressure (BP) was at least 140/90 mmHg or, regardless of BP,
if they were receiving antihypertensive therapy.2 International Journal of Nephrology
Table 1: Clinical, biochemical, and nutritional data.
Sex male/female 54/41
Age (years) 69.4 ± 14.4
Hemoglobin (mg/dl) 11.6 ± 1.6
Darbepoetin (μg/kg/week) 0.467 ± 0.47
eGFR (ml/min/1.73m2) 16.1 ± 7.0
Homocysteine, (μmol/L) 25.7 ± 11.8
IL-6 (pg/mL) 5.4 ± 5.3
hs-CRP (mg/dl) 1.3 ± 2.6
TNF-α (pg/mL) 11.6 ± 8.3
Fasting blood samples were collected to measure
hemoglobin, albumin, creatinine, triglycerides, and choles-
terol (total and HDL).
The glomerular ﬁltration rate (GFR) was calculated
according to the Modiﬁcation of Diet in Renal Disease
(MDRD) equation.
Plasma, collected using heparin as the anticoagulant,
was separated within 30 minutes of drawing and stored at
−80
◦C until analysis for hs-CRP, IL-6, TNF-α, and tHcy
(chemiluminescent assay) were performed. The modiﬁed
Subjective Global Nutritional Assessment (mSGA) was used
to evaluate the nutritional status.
The population was divided in 4 groups, depending if
their tHcy and mSGNA values were above or below the
mean level. The mean level of tHcy in our population was
25.7μmol/L and the mean value of mSGA was 12.2. The
groups were as follows: Group I-tHcy <25.7 μmol/L, mSGA
<12.2, n = 29; Group II-tHcy <25.7 μmol/L, mSGNA >12.2,
n = 18; Group III-tHcy >25.7 μmol/L, mSGA <12.2, n = 28;
Group IV tHcy >25.7 μmol/L, mSGNA >12.2, n = 20.
Statistical analysis—we ﬁrst did descriptive statistics;
valueswereexpressed asmean ±standard deviation; tocom-
pare diﬀerent groups we used the chi-square and ANOVA
tests;weusedthelinearregressionmodeltoevaluatetherela-
tionship between variables; we used the Pearson correlation
to evaluate the correlation between Hcy and inﬂammatory
and nutritional parameters; for survival analysis we used
the Kaplan-Meier method and for comparison of diﬀerent
groups survival we used the logrank test. The statistical
analysis was performed using SPSS 11.0 for Windows (SPSS,
Chicago, IL).The null hypothesis was rejected below the 5%
level (P < .05).
3. Results
We included 95 patients (f = 41, m = 54), with an
average age of 69.4 years, followed in our outpatient
clinic for 24.1 months. The original disease in 23 patients
(24.2%) was unknown; 30 patients (31.5%) had diabetic
nephropathy; 19 patients (20%) had hypertensive renal
disease;15patients(15.8%)hadchronicinterstitialdisease,5
(5.3%) had glomerulonephritis and 3 (3.2%) had polycystic
kidney disease. The prevalence of hypertension in our
study was 80% (76 patients), with 55.8% (53 patients)
Table 2: Correlation between Hcy and inﬂammatory/nutritional
parameters and level of renal function (Pearson correlation).
r P-value
IL-6 (pg/mL) 0.289 .005
hs-CRP (mg/dl) 0.208 .043
mSGA 0.102 .323
eGFR (mL/min/1.73m2) −0.294 .004
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Figure 1 :A c t u a r i a ls u r v i v a la t2 4m o n t h s .G r o u pI Vs h o w e dt h e
worst survival (logrank 8.31, P = .04).
receiving angiotensin-converting enzyme inhibitors and/or
angiotensin receptor blockers.
The characteristics of the population are showed in
Table 1.
Nutritional data was obtained from modiﬁed subjective
global nutritional assessment (mSGNA). Seven patients had
normalnutritionalstatus,68weremildmalnourishedand19
were moderate malnourished, while any patient had severe
malnutrition. The mean value of mSGA was 12.2 ± 3.6.
Using the Pearson correlation, we found an inverse
correlation between plasma tHcy and the eGFR and a
positive correlation between tHcy and hs-CRP and IL-6
(Table 2).
The four groups, divided according the tHCy and mSGA
values, were compared, and the results are displayed in
Table 3.
There were no signiﬁcant diﬀerences between groups
regarding sex distribution, and hemoglobin and CRP levels.
However, Group IV (patients with higher tHcy and mSGA
values)showedlowereGFR(P = .014),aswellashigherlevels
of IL-6 (P = .03) and TNF-α (P = .045).
During the follow-up 32 patients died: cardiovascular
disease [12]; cerebrovascular disease [4]; infections [9];
neoplasia [2]; cachexia [2]; unknown [3].
Using the Kaplan-Meier survival analysis we found the
following actuarial survival at 24 months of the diﬀerent
g r o u p s ,a sw ec a ns e ei nFigure 1:I= 85.9%; II = 71.8%; III
= 78.6%; IV = 50%, logrank = 8.31, P = .04.International Journal of Nephrology 3
Table 3: Comparison of the diﬀerent groups regarding clinical and biochemical parameters.
Group I Group II Group III Group IV P-value
tHcy <25.7 μmol/L, tHcy <25.7 μmol/L, tHcy >25.7 μmol/L, tHcy >25.7 μmol/L,
mSGA <12.2 mSGNA >12.2 mSGNA <12.2 mSGNA >12.2
Female/male 13/16 10/8 11/17 7/13 .599
Haemoglobin (g/dl) 11.8 ± 1.5 11.7 ± 1.4 11.4 ± 1.7 11.6 ± 1.9 .827
eGFR (ml/min/1.73 m2) 18.8 ± 7.1 16.4 ± 6.8 16.0 ± 7.1 12.2 ± 5.4 .014
Albumin (g/dL) 4.3 ± 0.4 4.0 ± 0.5 4.3 ± 0.5 4.1 ± 0.4 .032
Hcy (μmol/L) 16.5 ± 3.3 14,9 ± 4.4 32.3 ± 7.1 39.4 ± 9.0 .0001
mSGA 10 ± 1.8 15.4 ± 3.3 9.8 ± 1.6 15.9 ± 2.7 .0001
IL-6 (pg/ml) 3.3 ± 1.8 5.3 ± 3.4 5.3 ± 3.6 8.9 ± 9.3 .03
hs-CRP (mg/dl) 0.45 ± 0.6 1.3 ± 2.2 1.5 ± 2.8 2.2 ± 3.8 .122
TNF-α (pg/ml) 8.5 ± 3.3 11.6 ± 6.1 12.3 ± 6.3 15.1 ± 14.3 .045
4. Discussion
Protein-energy malnutrition is very common in patients
with chronic renal failure (CRF), with signs of malnutrition
observed in 25%–40% of predialysis patients [10, 12]. We
also know that the risk of death from all causes and from
cardiovascular (CV) disease is increased since stage 3 of
CKD [13, 14]. Classical risk factors, such as hypertension,
dislipidemia or hyperuricemia, as well new risk factors,
such inﬂammation, hyperhomocystenemia or endothelial
dysfunction, contribute to this increased risk of cardiovas-
cular mortality [15]. Hyperhomocysteinemia has attracted
growinginterestinrecentyears[10].Epidemiologicalstudies
have shown that there is strong evidence that moderate
elevation of total homocysteine levels is an independent
risk factor for atherosclerosis in the general population [9,
10, 16]. Moderate hyperhomocysteinemia is present in the
early stages of renal failure and increases along with the
deterioration of renal function [9, 10, 17]. The prevalence of
hyperhomocysteinemia is 85%–100% among patients with
advanced CRF [10]. The mechanisms by which plasma Hcy
levels increase in CRF are not fully understood. Reduced
renal excretion and decreased renal uptake probably do not
play a major role, since renal elimination of Hcy is of any
signiﬁcance in normal humans [17, 18].
Suliman et al. showed recently that high levels of
homocysteine were not an independent risk factor for
atherosclerosis [8]. They found that a low Hcy concentration
was associated with higher all-cause and cardiovascular
mortality, although this correlation could be attributed,
at least in part, to the inﬂuence of various confounders,
including markers of wasting and inﬂammation on Hcy
levels [8–11]. In their work, after adjustment for all con-
founding factors which potentially could inﬂuence Hcy
concentration, a high Hcy level showed only a trend towards
a positive association with increased all-cause and cardio-
vascular mortality. Although not statistically signiﬁcant, the
all-cause and CV mortality were, respectively, 27% and
22% higher for high tHcy compared with low tHcy levels
[8].
More recently, Kalantar-Zadeh et al., also reported that
the mortality rate was higher in the lowest Hcy quartile [7].
Nevertheless,otherauthorshavefoundinCKDpatientsthat,
similar to the general population, tHcy is associated with an
increased risk of CV events and mortality [19].
In fact, association between low homocysteinemia and
atherosclerosis does not have any theoretical plausibility,
and so other factors must come into place to explain why
some cardiovascular risk factors are strongly correlated with
a decreased rate of cardiovascular events and death. This
point of view was explored by Ducloux et al. in dialysis
patients [20] .T h e yf o u n dap o s i t i v ec o r r e l a t i o nb e t w e e n
homocysteine levels and CV mortality in dialysis patients
without a chronic state of inﬂammation-malnutrition, and
an inverse relationship between Hcy and all-cause and CV
mortality in dialysis patients with chronic inﬂammation-
malnutrition syndrome.
In our work we tried to evaluate if such association is
already present in predialysis patients, and if there was any
diﬀerence in mortality between the patients. We divided our
population according to plasma Hcy levels and nutritional
stateandfoundthathigherlevelsofHcywereassociatedwith
a higher mortality rate in those patients who had a state of
inﬂammation-malnutrition.
These results are in contradiction with those found by
Ducloux et al. probably because they used the values of CRP
andalbumintodeﬁnethepresenceofchronicinﬂammation-
malnutrition state (CIMS). Albumin is a major determinant
of tHcy levels [8], being hypoalbuminemia associated with
low tHcy levels. Serum albumin levels are inﬂuenced by
nutritional and nonnutritional factors [12, 21]a n dp r o b a b l y
albumin is not the most accurate marker of malnutrition.
To evaluate the nutritional status, we used the mSGA and in
the group of patients with higher mSGA (worse nutritional
status), the albumin level was higher than the value found
by Ducloux et al. in their group of patients with CIMS. This
factcouldhavedeterminedhighertHcylevelsinourpatients.
We also found a positive correlation between tHcy levels and
markers of inﬂammation, namely, IL-6 and TNF-α. This is
again in contrast with Ducloux et al. These authors found an
inverse association between CRP and tHcy. Using diﬀerent
malnutrition and inﬂammation markers than Ducloux et
al., we found that inﬂammation and malnutrition was
associated with higher levels of tHcy. Furthermore, mortality4 International Journal of Nephrology
was higher in patients with inﬂammation-malnutrition and
higher tHcy.
We believe that both factors act in synergy and that
Hcy impact on mortality could not be evaluated without
considering other factors, namely, inﬂammation. Moreover,
our study shows that the impact of Hcy is dependent on the
nutritional and inﬂammatory status.
One of the drawbacks of our study was the lack
of evaluation of folate and vitamin B12 concentrations,
since inadequate concentrations are contributing factors for
hyperhomocysteinemia [16, 22]. More studies, with more
patients, longer follow up, and wider biochemical evaluation
are needed to try to answer these questions.
In conclusion, we found that higher levels of homocys-
teine can be associated with higher mortality in predialysis
patients, as long as they are associated with malnutrition and
inﬂammation.
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